RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2015 /PRNewswire-iReach/ -- Qualyst Transporter Solutions (QTS) is pleased to announce that two poster presentations and an Industry-Sponsored Symposium on its proprietary B-CLEAR® technology, and the technology’s ability to predict cholestasis, have been accepted at the upcoming 20th North American Meeting of the International Society for the Study of Xenobiotics (ISSX), being held October 18 - 22 in Orlando, FL.
The focus of these presentations is to highlight the importance of basolateral efflux in determining hepatotoxicity as well as in controlling intracellular concentrations of both endogenous and exogenous compounds. Ignoring the effects of basolateral efflux could result in a significant overprediction of biliary clearance. Understanding this issue requires technologies that can separate both basolateral and biliary efflux. Many companies claim they can measure biliary efflux, while, in fact, they are unknowingly measuring both basolateral and biliary pathways together.
“Hepatic basolateral efflux transporters are an under-recognized and under appreciated class of transporters,” said Kenneth Brouwer, Chief Scientific Officer of QTS. “Scientists from industry and academia are starting to realize that hepatic models that do not separate and measure basolateral and biliary efflux can produce significantly inaccurate and misleading data. We are happy to be contributing to the research that is bringing this issue to light,” said Dr. Brouwer.
“B-CLEAR® technology is a proprietary parallel incubation methodology that is designed to uniquely and separately quantitate uptake, basolateral efflux, and biliary efflux,” states Christopher Black, CEO of QTS. “No other model system or technology out there can claim this capability. We believe this topic is of critical concern because there are many claims around measuring biliary efflux that actually measure both biliary and basolateral efflux together all of which misinform researchers. There is an urgent need for good science and proper models,” said Dr. Black.
ISSX poster titles and author:
- Poster: “Transporter Induction: A Potentially Important Pathway for the Prevention of Cholestatic Hepatotoxicity”
Presenting Author: Kenneth R. Brouwer, Ph.D. RPh., Chief Scientific Officer, QTS - Poster: “Intracellular Concentrations of Endogenous Bile Acids in Sandwich-Cultured Hepatocytes: Relevance For Prediction of Cholestasis”
Presenting Author: Kenneth R. Brouwer, Ph.D. RPh., Chief Scientific Officer, QTS
Industry-Sponsored Breakfast Symposium*, hosted by Qualyst Transporter Solutions:
Session Topic: Why Basolateral Efflux Transporters Matter
Speaker: Kim L. R. Brouwer, Pharm.D., Ph.D., Professor and Associate Dean for Research and Graduate Education, The University of North Carolina at Chapel Hill
When: 7:30AM 8:45AM on Tuesday, October 20 ISS Session #4
Where: Hilton Orlando Bonnet Creek Resort, Orlando FL
The focus of the event will be the emerging importance of basolateral efflux in hepatic models. Attendees can register at: http://www.qualyst.com/iss-register.html
About Qualyst Transporter Solutions, LLC
Qualyst Transporter Solutions commercializes novel and proprietary drug transport and hepatobiliary disposition products for research in induction, hepatotoxicity, cholestasis, clearance, and/or drug interactions by combining physiologic transporter function with a proven method that can separately measure both basolateral and biliary efflux. Our products and contract services provide clinically-relevant answers to liver-related questions through the use of the proprietary B-CLEAR® technology, an integrated whole-cell sandwich-cultured hepatocyte platform that yields physiologic intracellular concentrations by ensuring proper metabolism and transport function. B-CLEAR® technology offers superior in vitro hepatic insight, and is the only model that separates basolateral from biliary efflux by using a parallel incubation methodology. In addition, Qualyst Transporter Solutions has pioneered an industry-accepted standard of hepatocyte function for cryopreserved human hepatocytes called Transporter Certified, which is available from most hepatocyte providers. B-CLEAR® technology is covered by US (# 6780580), EU (#1163517) and JP (#4451570) patents issued and pending. For additional information, please refer to the company’s web site at www.qualyst.com or call (919) 313- 6500.
*This session is an industry-sponsored symposium. Although not an official part of the 20th North American ISSX Meeting, this program has been reviewed and its presentation permitted by the meeting organizers.
Media Contact:Chris Black, Qualyst Transporter Solutions, 919-313-6500, chrisblack@qualyst.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Qualyst Transporter Solutions
Help employers find you! Check out all the jobs and post your resume.
